Methods of treating obesity with purine related compounds
AssigneeThe Pennsylvania Research Corporation
InventorKathryn F. LaNoue
Life of this patent
Estimating the term…
Abstract
There is disclosed a method of treating obesity in warm-blooded animals, including humans, as well as a method of increasing the muscle mass to fat ratio in farm animals. The methods entail administering to an animal in need thereof, an effective amount of certain 8-phenylxanthines substituted in the 3- or 4-position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acetic grouping.
Claims20
A method of treating obesity in a warm-blooded animal, the method comprising administering to said animal:
- an effective anti-obesity amount of a compound of Formula I ##STR3## wherein:
- X.sub.1 and X.sub.2 are the same or different and are hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.7-12 aralkyl optionally substituted in the aryl ring by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, halo, nitro, amino, azido or cyano, provided that both X.sub.1 and X.sub.2 are not hydrogen;
- one of X.sub.3 and X.sub.4 is hydrogen, C.sub.1-6 alkyl, trifluoromethyl, C.sub.1-6 alkoxy, halo, nitro, amino, C.sub.1-6 alkoxycarbonyl or carboxy and the other is a group--Y--Z where Y is C.sub.2-6 alkenylene, or C.sub.3-6 alkenyleneoxy, C.sub.2-6 alkynylene or C.sub.3-6 alkynyleneoxy and Z is carboxy, sulphonyl or phosphonyl or a C.sub.1-9 alkyl ester, a C.sub.7-12 aralkyl ester or a C.sub.6-12 aryl ester thereof, or a 5-tetrazolyl;
- and
- X.sub.5 and X.sub.6 are the same or different and are oxygen or sulphur;
- or a pharmaceutically acceptable salt thereof;
- or pharmaceutically acceptable solvate thereof.
A method of increasing the ratio of muscle mass to fat in a farm animal, the method comprising administering to said animal:
- an effective amount of a Formula I compound for increasing the ratio of muscle mass to fat in said animal ##STR4## wherein:
- X.sub.1 and X.sub.2 are the same or different and are hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.7-12 aralkyl optionally substituted in the aryl ring by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, halo, nitro, amino azido or cyano, provided that both X.sub.1 and X.sub.2 are not hydrogen;
- one of X.sub.3 and X.sub.4 is hydrogen, C.sub.1-6 alkyl, trifluoromethyl, C.sub.1-6 alkoxy, halo, nitro, amino, C.sub.1-6 alkoxycarbonyl or carboxy and the other is a group --X--Z where Y is C.sub.2-6 alkenylene, or C.sub.3-6 alkenyleneoxy, C.sub.2-6 alkynylene or C.sub.3-6 alkynyleneoxy and Z is carboxy, sulphonyl or phosphonyl or a C.sub.1-9 alkyl ester, a C.sub.7-12 aralkyl ester or a C.sub.6-12 aryl ester thereof, or a 5-tetrazolyl;
- and
- X.sub.5 and X.sub.6 are the same or different and are oxygen or sulphur;
- or a pharmaceutically acceptable salt thereof;
- or a pharmaceutically acceptable solvate thereof.
Dependencies are inferred from the claim text.